-transparent.png){kind=logo}
Twenty-nine patients with a diagnosis of advanced adenocarcinoma of the stomach with gross unresectable or measurable residual disease and no prior therapy were entered into a study utilizing diaziquone (AZQ) in an intermittent 3-week schedule of 40 mg/m2. Of 28 eligible patients, 1 (4%) experienced a partial response, 7 (25%) had stable disease of no response, and 18 (64%) developed increasing disease. Two (7%) were unevaluable. Median survival was 3.8 months. Major toxicities were myelosuppression and gastrointestinal, 11 of which were considered to be life-threatening. AZQ used as a single intermittent agent appears to have no significant activity to warrant use in untreated advanced gastric carcinoma. However, recognizing the short plasma half-life of AZQ, significant responses by other schedules of administration are not precluded.
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
January 1994,
Investigational new drugs,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
June 1985,
Cancer treatment reports,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
December 1987,
Cancer treatment reports,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
September 1985,
Cancer treatment reports,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
May 1985,
Cancer treatment reports,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
January 1994,
Investigational new drugs,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
January 1997,
Investigational new drugs,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
February 1990,
Investigational new drugs,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
May 1982,
Cancer treatment reports,
R P Pugh, and
T Fleming, and
J T Guy, and
J K Weick, and
J H Ward
July 2001,
Urologic oncology,
